National News

Moroccan Ministry of Health Approves Price Reductions for Cancer and Blood Disorder Medications

The Ministry of Health and Social Protection has approved significant price reductions for a number of essential medications intended for the general public and hospital institutions. According to official data, this move aims to alleviate the financial burden on patients and enhance access to essential treatments across the Kingdom.

Details of the Price Review for Vital Medications

This price revision, contained in Ministerial Decree No. 2157.26 published in the Official Gazette No. 7552 on October 15, 2026, covers a group of vital medications mainly used in treatment protocols for cancer, chronic immune diseases, and drugs related to blood clotting disorders.

This new measure comes within the framework of updating and supplementing the previous decree No. 787.14 regarding the setting of sale prices for medicines to the public and to hospital institutions. According to available data, the list of reductions covers a broad sector of drugs, including both original (innovative) medicines and generics, which contributes to providing multiple therapeutic alternatives at more competitive prices for citizens.

Objectives of the New Pharmaceutical Strategy

These price adjustments are part of the general strategy adopted by the Ministry to upgrade the national pharmaceutical sector and regulate prices in line with the purchasing power of citizens, especially social groups suffering from chronic illnesses that require long-term and costly treatment protocols.

This regulatory step aims to ensure the continuity of basic healthcare and facilitate patients’ access to approved medicines within national treatment protocols under suitable conditions, thereby reducing the material costs incurred from long-term treatments.

Related Articles

💬 Share your opinion

We welcome constructive opinions and ask you to maintain politeness.

0 comments

Leave a Comment

Back to top button